New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.

Autor:	Tamargo J; Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid, Spain., Agewall S; Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University, Oslo, Norvay., Borghi C; Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, Bologna, Italy., Ceconi C; Unit of Cardiologia, ASST Garda, Desenzano del Garda, Italy., Cerbai E; Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, Italy., Dan GA; 'Carol Davila' University of Medicine, Colentina University Hospital, Bucharest, Romania., Ferdinandy P; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.; Pharma hungary Group, Szeged, Hungary., Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark)., Rocca B; Section of Pharmacology, Catholic University School of Medicine, Rome, Italy., Sulzgruber P; Department of Medicine, Division of Cardiology, Medical University of Vienna, Austria., Semb AG; Preventive Cario-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital, Oslo, Norway., Sossalla S; Department of Internal Medicine II, University Regensburg, Germany., Niessner A; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria., Kaski JC; Molecular and Clinical Sciences Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK., Dobrev D; Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen, Essen, Germany.; Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Canada.; Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA.
Jazyk:	angličtina
Zdroj:	European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2023 May 11. Date of Electronic Publication: 2023 May 11.
DOI:	10.1093/ehjcvp/pvad034
Abstrakt:	Cardiovascular diseases (CVD) remain the leading cause of death worldwide and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and better safety profiles. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2022 including the approval of first-in-class drugs that open new avenues for the treatment of obstructive hypertrophic cardiomyopathy (mavacamten), type 2 diabetes mellitus (tirzepatide), and heart failure (HF) independent of left ventricular ejection fraction (sodium-glucose cotransporter 2 inhibitors). We also dealt with fixed dose combination therapies repurposing different formulations of "old" drugs with well-known efficacy and safety for the treatment of patients with acute decompensated HF (acetazolamide plus loop diuretics), atherosclerotic cardiovascular disease (moderate-dose statin plus ezetimibe), Marfan syndrome (angiotensin receptor blockers plus β-blockers), and secondary cardiovascular prevention (i.e. low-dose aspirin, ramipril and atorvastatin), thereby filling existing gaps in knowledge, and opening new avenues for the treatment of CVD. Clinical trials confirming the role of dapagliflozin in patients with HF and mildly reduced or preserved ejection fraction, long-term evolocumab to reduce the risk of cardiovascular events, vitamin K antagonists for stroke prevention in patients with rheumatic heart disease-associated atrial fibrillation, antibiotic prophylaxis in patients at high risk for infective endocarditis before invasive dental procedures, and vutrisiran for the treatment of hereditary transthyretin-related amyloidosis with polyneuropathy were also reviewed. Finally, we briefly discuss recent clinical trials suggesting that FXIa inhibitors may have the potential to uncouple thrombosis from hemostasis and attenuate/prevent thromboembolic events with minimal disruption of hemostasis. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu